<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459457</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai 2</org_study_id>
    <nct_id>NCT02459457</nct_id>
  </id_info>
  <brief_title>A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer</brief_title>
  <official_title>A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University Shanghai Cancer Center Minhang Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determined the best scheme in paclitaxel and
      cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy
      for patients with local advanced esophageal Squamous Cell Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1year, 2 years, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">321</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Paclitaxel and Cisplatin (TP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel and Fluorouracil (TF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel and Carboplatin（TC）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Cisplatin</intervention_name>
    <description>patients get Paclitaxel and Cisplatin according to protocol</description>
    <arm_group_label>Paclitaxel and Cisplatin (TP)</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Fluorouracil</intervention_name>
    <description>patients get Paclitaxel and Fluorouracil according to protocol</description>
    <arm_group_label>Paclitaxel and Fluorouracil (TF)</arm_group_label>
    <other_name>TF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and Carboplatin</intervention_name>
    <description>patients get Paclitaxel and Carboplatin according to protocol</description>
    <arm_group_label>Paclitaxel and Carboplatin（TC）</arm_group_label>
    <other_name>TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>1.8Gy/d, d1-5/week, 34Fx</description>
    <arm_group_label>Paclitaxel and Cisplatin (TP)</arm_group_label>
    <arm_group_label>Paclitaxel and Fluorouracil (TF)</arm_group_label>
    <arm_group_label>Paclitaxel and Carboplatin（TC）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        To be eligible for this study, patient must fulfill all of the following criteria:

          1. Histologically confirmed esophageal squamous cell carcinoma

          2. Clinical stages II, III or IVa based on the 6th UICC-TNM classification

          3. No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer,
             except for non-curative resection by EMR/ESD.

          4. Aged 18-75 years

          5. Adequate organ functions

               1. White blood cell (WBC) ≥3×109⁄L

               2. Absolute neutrophil counts (ANC) ≥1.5×109⁄L

               3. Hemoglobin (Hb) ≥10g⁄dl

               4. Platelet (Plt) ≥100×109⁄L

               5. Total bilirubin &lt;1.5 upper limit of normal (ULN)

               6. Aspartate transaminase (AST) ≤2.5 ULN

               7. Alanine aminotransferase (ALT) ≤2.5 ULN

               8. Creatinine ≤1.5 ULN

          6. ECOG PS of 0-2

          7. Life expectancy ≥3 months

          8. Written informed consent

        Exclusion criteria Patients fulfilling any of the following criteria are ineligible for
        this study.

          1. Esophageal perforation or hematemesis

          2. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas)
             carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ
             curatively treated and disease free for a minimum of 3 months)

          3. Received thoracic, abdominal or craniocerebral surgery within 30 days

          4. Enrolled in other clinical trials within 30 days

          5. Unstable angina and/or congestive heart failure requiring hospitalization within 6
             months

          6. Severe psychiatric disease

          7. Pregnancy, lactation or unwillingness to adopt contraception

          8. Drug addiction

          9. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition

         10. Patients with hearing impairment or sensory-motor neuropathy of WHO grade &gt; 1

         11. History of radiotherapy in the planning area

         12. Other ineligible conditions according to researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuaile Zhao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>+86 18017312534</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuaile Zhao, MD</last_name>
    <phone>+86 18017312534</phone>
    <email>kuaile_z@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun Chen, MM</last_name>
    <phone>8621-64175590</phone>
    <email>chenyun_qz@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuaile Zhao, M.D</last_name>
      <phone>+86 18017312534</phone>
      <email>kuaile_z@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>esophageal squamous cell carcinoma</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

